Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01081782 · ClinicalTrials.gov registry record · Phase 2
A Study of the Safety and Efficacy of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis
A Phase 2 study of Multiple Sclerosis, sponsored by Ono Pharma USA.
- Completed
- Registry status
- Phase 2
- Development phase
- 407
- Enrollment target
- 20
- Study locations
NCT01081782: Completed Phase 2 study of Multiple Sclerosis, sponsored by Ono Pharma USA.
NCT01081782 is a Phase 2 study of Multiple Sclerosis that has completed, run by Ono Pharma USA. The registered enrollment target is 407 participants, below the 584-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (30% lower). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01081782, a Phase 2 study of Multiple Sclerosis, has completed, sponsored by Ono Pharma USA.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 407 participants
- Enrollment target
- 20
- Study locations
Study Summary
The objective of this study is to evaluate the safety and efficacy of ONO-4641 in patients with relapsing-remitting multiple sclerosis over a 26-week treatment period.
Conditions Studied
Interventions
- DRUG ONO-4641
- DRUG ONO-4641 placebo
Study Locations (20)
Florida
- Ormond Beach Clinical Site 129 - Ormond Beach
- Sarasota Clinical Site 116 - Sarasota
- Sarasota Clinical Site 117 - Sarasota
North Carolina
- Charlotte Clinical Site 125 - Charlotte
- HighPoint Clinical Site 128 - HighPoint
- Raleigh Clinical Site 103 - Raleigh
Colorado
- Aurora Clinical Site 132 - Aurora
- Fort Collins Clinical Site 123 - Fort Collins
Indiana
- Fort Wayne Clinical Site 111 - Fort Wayne
- Indianapolis Clinical Site 121 - Indianapolis
Michigan
- Detroit Clinical Site 104 - Detroit
- Farmington Hills Clinical Site 126 - Farmington Hills
Arizona
- Tucson Clinical Site 133 - Tucson
Connecticut
- Fairfield Clinical Site 110 - Fairfield
Illinois
- Northbrook Clinical Site 135 - Northbrook
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 407 participants |
| Start Date | 2010-03 |
| Est. Completion | 2011-12 |
| Phase | Phase 2 |
What the finished NCT01081782 record still lists
NCT01081782 is an interventional study that assigns participants to a tested intervention. The registered 407 participants enrollment target is mid-sized for trials with a published cap, below the 584-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (30% lower).
The record links to 1 condition, with Multiple Sclerosis appearing as the primary indexed condition, and to 2 interventions - of which ONO-4641 is the first listed.
NCT01081782 names 20 study sites across 13 states, led by Florida, North Carolina, Colorado.
Frequently Asked Questions
What is clinical trial NCT01081782 about?
NCT01081782 is a clinical study titled "A Study of the Safety and Efficacy of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis". The objective of this study is to evaluate the safety and efficacy of ONO-4641 in patients with relapsing-remitting multiple sclerosis over a 26-week treatment period.
What is the current status of trial NCT01081782?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 407 participants. The study started on 2010-03. Estimated completion is 2011-12.
What conditions does trial NCT01081782 study?
This clinical trial studies the following conditions: Multiple Sclerosis.
What interventions are being tested in trial NCT01081782?
The interventions under investigation include: ONO-4641 (DRUG), ONO-4641 placebo (DRUG).
Who is sponsoring clinical trial NCT01081782?
This trial is sponsored by Ono Pharma USA, which has 17 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01081782 being conducted?
This trial has 20 study locations across Arizona, Colorado, Connecticut, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01081782's enrollment target sits among peer trials
407 46th of 315 higher than 270 of 315 other Multiple Sclerosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Sclerosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Mechanisms of Cannabidiol in Persons With MS: the Role of Sleep and Pain Phenotype
RECRUITING · Phase 2
-
Metformin as an add-on or Monotherapy in Treatment of Aging People With Multiple Sclerosis (MS)
RECRUITING · Phase 2
-
A Study to Assess Bioequivalence of Two Subcutaneous (SC) Formulations of Ocrelizumab in Participants With Multiple Sclerosis (MS)
RECRUITING · Phase 2
-
Solriamfetol for the Treatment of Multiple Sclerosis Fatigue
RECRUITING · Phase 2
-
A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ≤55 Years
RECRUITING · Phase 2
-
Efficacy of Cognitive Behavioral Therapy for Insomnia to Treat Insomnia Symptoms in Individuals With Multiple Sclerosis
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06735534 · 407 participants · NA
Repeat Ablation of Persistent Atrial Fibrillation, Including Mitral Isthmus Catheter Ablation, With the FARAPULSE Pulsed Field Ablation System
- NCT07094516 · 407 participants · Phase 2
A Clinical Trial to Learn About the Effects of VHB937 in People With Early Alzheimer's Disease
- NCT04835428 · 408 participants · NA
STAND - Study of the AGN1 LOEP SV Kit Compared to PMMA in Patients With Vertebral Compression Fractures
- NCT05836324 · 408 participants · Phase 1
A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia